

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration**

[Docket No. FDA-2023-N-0008]

**Request for Nominations for Voting Members for the Genetic Metabolic Diseases Advisory Committee; Amendment of Notice****AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing an amendment to the notice of the request for nominations for voting members excluding consumer and industry representatives, to serve on the Genetic Metabolic Diseases Advisory Committee (the Committee) in the Center for Drug Evaluation and Research. This request for nominations was announced in the **Federal Register** of December 13, 2023. The amendment is being made to reflect a change in the **DATES** portion of the document. There are no other changes.

**FOR FURTHER INFORMATION CONTACT:** Moon Choi, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-2894, email: [GEMDAC@fda.hhs.gov](mailto:GEMDAC@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of December 13, 2023 (88 FR 86337), FDA announced a request for nominations for voting members excluding consumer and industry representatives, to serve on the Genetic Metabolic Diseases Advisory Committee. On page 86337, in the second column, the **DATES** portion of the document is changed to read as follows:

Nominations received on or before March 12, 2024, will be given first consideration for membership on the Committee. Nominations received after March 12, 2024, will be considered for nomination to the Committee as later vacancies occur.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

Dated: February 12, 2024.

**Lauren K. Roth,***Associate Commissioner for Policy.*

[FR Doc. 2024-03302 Filed 2-15-24; 8:45 am]

**BILLING CODE 4164-01-P****DEPARTMENT OF HEALTH AND HUMAN SERVICES****Health Resources and Services Administration****Advisory Committee on Training in Primary Care Medicine and Dentistry Meeting Cancellation****AGENCY:** Health Resources and Services Administration; Department of Health and Human Services.**ACTION:** Notice of meeting cancellation.

**SUMMARY:** This is to notify the public that the March 25-26, 2024, meeting of the Advisory Committee on Training in Primary Care Medicine and Dentistry is cancelled.

**FOR FURTHER INFORMATION CONTACT:** Shane Rogers, Designated Federal Officer, Advisory Committee on Training in Primary Care Medicine and Dentistry, 5600 Fishers Lane, Room 15N142, Rockville, Maryland 20857, telephone: (301) 443-5260 or email: [srogers@hrsa.gov](mailto:srogers@hrsa.gov).

**SUPPLEMENTARY INFORMATION:** This meeting was announced in the **Federal Register** on Friday, December 15, 2023 (88 FR 86909). Future meetings will be held on August 2, 2024, and another date this calendar year that will be announced at least 30 days before the meeting date through the **Federal Register**.

**Maria G. Button,***Director, Executive Secretariat.*

[FR Doc. 2024-03261 Filed 2-15-24; 8:45 am]

**BILLING CODE 4165-15-P****DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Library of Medicine; Notice of Meeting Amended Notice of Meeting**

Notice is hereby given of a change in the virtual meeting of the Biomedical Library, Informatics and Data Science Review Committee, May 17-18, 2024, which was published in the **Federal Register** on December 21, 2023, 2023, 88 FR 88407.

The meeting will be amended to change the meeting dates from March 7-8, 2024, to March 7, 2024. The meeting will be closed to the public.

Dated: February 12, 2024.

**Miguelina Perez,***Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024-03212 Filed 2-15-24; 8:45 am]

**BILLING CODE 4140-01-P****DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Integration of Novel Measures for Improved Classification of Type 2 Diabetes Consortium Review.

*Date:* March 19, 2024.*Time:* 10:30 a.m. to 6:00 p.m.*Agenda:* To review and evaluate cooperative agreement applications.

*Place:* National Institutes of Health, NIDDK Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Ann A. Jerkins, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7119, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, 301-594-2242, [jerkinsa@nidk.nih.gov](mailto:jerkinsa@nidk.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: February 12, 2024.

**Miguelina Perez,***Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024-03211 Filed 2-15-24; 8:45 am]

**BILLING CODE 4140-01-P****DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting**

Pursuant to section 1009 of the Federal Advisory Committee Act, as

amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; NIDDK RC2 Review.  
*Date:* March 21, 2024.

*Time:* 11:30 a.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, NIDDK Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Elena Sanovich, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7351, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, 301-594-8886, [sanoviche@mail.nih.gov](mailto:sanoviche@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: February 12, 2024.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024-03208 Filed 2-15-24; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would

constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; Quantification of Drugs of Abuse and Related Substances Compounds in Biological Specimens.

*Date:* March 1, 2024.

*Time:* 1:00 p.m. to 3:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.

*Contact Person:* Ipolia R. Ramadan, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-4471, [ramadanir@mail.nih.gov](mailto:ramadanir@mail.nih.gov).

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research.

*Date:* March 12, 2024.

*Time:* 2:00 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.

*Contact Person:* Sudhirkumar U. Yanpallewar, M.D., Scientific Review Officer, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443-4577, [sudhirkumar.yanpallewar@nih.gov](mailto:sudhirkumar.yanpallewar@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: February 13, 2024.

**Lauren A. Fleck,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024-03327 Filed 2-15-24; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOMELAND SECURITY

### U.S. Customs and Border Protection

[Docket No. USCBP-2024-0001]

#### Commercial Customs Operations Advisory Committee

**AGENCY:** U.S. Customs and Border Protection (CBP), Department of Homeland Security (DHS).

**ACTION:** Committee management; notice of open Federal advisory committee meeting.

**SUMMARY:** The Commercial Customs Operations Advisory Committee (COAC) will hold its quarterly meeting on Wednesday, March 6, 2024, in Charleston, SC. The meeting will be open for the public to attend in person or via webinar. The in-person capacity is limited to 75 persons for public attendees.

**DATES:** The COAC will meet on Wednesday, March 6, 2024, from 1 p.m. to 5 p.m. eastern standard time (EST). Please note that the meeting may close early if the committee has completed its business. Registration to attend in-person and comments must be submitted no later than March 1, 2024.

**ADDRESSES:** The meeting will be held at the Doubletree Hilton, 7401 Northwood Boulevard, Charleston, SC 29406 in the Lower/Upper Altitude Ballroom. For virtual participants, the webinar link and conference number will be posted by 5 p.m. EST on March 5, 2024, at <https://www.cbp.gov/trade/stakeholder-engagement/coac>. For information or to request special assistance for the meeting, contact Mrs. Latoria Martin, Office of Trade Relations, U.S. Customs and Border Protection, at (202) 344-1440, as soon as possible.

Comments may be submitted by one of the following methods:

- **Federal eRulemaking Portal:** <http://www.regulations.gov>. Search for Docket Number USCBP-2024-0001. To submit a comment, click the "Comment" button located on the top-left hand side of the docket page.

- **Email:** [tradeevents@cbp.dhs.gov](mailto:tradeevents@cbp.dhs.gov). Include Docket Number USCBP-2024-0001 in the subject line of the message.

Comments must be submitted in writing no later than March 1, 2024, and must be identified by Docket No. USCBP-2024-0001. All submissions received must also include the words "Department of Homeland Security." All comments received will be posted without change to <https://www.cbp.gov/trade/stakeholder-engagement/coac/coac-public-meetings> and [www.regulations.gov](http://www.regulations.gov). Therefore, please refrain from including any personal information you do not wish to be posted. You may wish to view the Privacy and Security Notice, which is available via a link on [www.regulations.gov](http://www.regulations.gov).

**FOR FURTHER INFORMATION CONTACT:** Mrs. Latoria Martin, Office of Trade Relations, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue NW, Room 3.5A, Washington, DC 20229, (202) 344-1440; or Ms. Felicia M. Pullam, Designated Federal Officer, at (202) 344-1440 or via email at [tradeevents@cbp.dhs.gov](mailto:tradeevents@cbp.dhs.gov).